Location History:
- Osaka, JP (2015)
- Takarazuka, JP (2016)
Company Filing History:
Years Active: 2015-2016
Title: Hiroyuki Ushio: Innovator in Medicinal Chemistry
Introduction
Hiroyuki Ushio is a prominent inventor based in Takarazuka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel therapeutic agents. With a focus on cytokine production from T cells, his work has the potential to impact various medical conditions.
Latest Patents
Hiroyuki Ushio holds 2 patents, showcasing his innovative approach to medicinal compounds. His latest patents include:
1. **Amidopyridine derivative and use thereof** - This invention relates to novel amidopyridine derivatives that serve as medicinal agents. These derivatives are useful as prophylactic or therapeutic agents for diseases linked to cytokine production from T cells. The patent provides a specific amidopyridine derivative or a pharmacologically acceptable salt thereof.
2. **Amide derivative and use thereof** - This patent describes a novel amide derivative that functions as a medicinal agent. Similar to his previous work, this derivative is aimed at treating diseases associated with cytokine production from T cells. It includes an amide derivative or a pharmacologically acceptable salt or solvate of the derivative as the active ingredient.
Career Highlights
Hiroyuki Ushio is affiliated with Mitsubishi Tanabe Pharma Corporation, where he continues to advance his research in medicinal chemistry. His work is characterized by a commitment to developing effective therapeutic solutions for various health challenges.
Collaborations
Hiroyuki Ushio has collaborated with notable colleagues, including Masayuki Watanabe and Hiroyuki Furukawa. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Hiroyuki Ushio's contributions to medicinal chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic agents targeting cytokine-related diseases.